Loading clinical trials...
Loading clinical trials...
SPIRIT 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain
Conditions
Interventions
Relugolix
Estradiol/norethindrone acetate
+2 more
Locations
91
United States
Andalusia
Andalusia, Alabama, United States
Washington DC
Washington D.C., District of Columbia, United States
Aventura
Aventura, Florida, United States
Deland
DeLand, Florida, United States
Hialeah
Hialeah, Florida, United States
Hialeah
Hialeah, Florida, United States
Start Date
November 1, 2017
Primary Completion Date
April 1, 2020
Completion Date
May 31, 2021
Last Updated
June 28, 2021
NCT04265781
NCT03204318
Lead Sponsor
Myovant Sciences GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions